Furstenthal et al. now reveal a new pathway regulating Xic1 ubiquitination and degradation in Xenopus.In contrast with the current model, direct phosphorylation of Xic1 by cyclin E/Cdk2 is not ...

With the discovery that vitamin D regulates the expression of an important antimicrobial peptide gene, exciting research findings are revealing and characterizing new pathways regulated by vitamin ...

They examined how MZ1 was able to hold onto target protein Brd4 BD2 and direct it toward UBE2R1, a member of the ubiquitin-conjugating enzyme family, demonstrating the proficiency of MZ1 to position ...

CDK2 and Cyclin ... degradation, and key downstream pharmacodynamic markers including CD69, IL-2, IL-6, and IL-17. Submit an IND application for MRT-8102 in H1 2025. Nominate a CDK2 program ...

2010 Future Medicine Ltd. Cite this: Cyclin-dependent Kinase Inhibitor p27 as a Prognostic Biomarker and Potential Cancer Therapeutic Target - Medscape - Dec 01, 2010.

However, the complex relationship between microbes and microplastics presents both opportunities and challenges, leading to a nuanced understanding of their applications in degradation. This paper ...

June 3, 2024 — Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require ...

Garden Pathways, a nonprofit providing mentoring to ... into Delano with a ribbon-cutting Monday at 1109 High St., Suite D. The 9 a.m. ceremony is to include speakers President/CEO Karen Goh ...

Ph.D., in the George W. Agak Laboratory and colleagues at the David Geffen School of Medicine at UCLA are the first to ...

Within specific indications, CID-078 single agent activity was correlated with RB1 mutation, high E2F target, or G2M checkpoint hallmark pathway scores ... with dual cyclin A and B RxL inhibitory ...

Earp, JD, Ph.D., CEO of Circle Pharma ... this observation and so I am extremely excited to see Circle Pharma’s cyclin A/B RxL inhibitor move into the clinic." All patients in the cohort ...